The anti-cancer agent paclitaxel (Taxol) stabilizes microtubules leading to G2/M cell cycle arrest and apoptotic cell death. In order to analyse the molecular mechanisms of Taxol-induced cytotoxicity, we studied the involvement of mitogen-activated protein kinases (MAPK) ERK and p38 as well as the p53 pathways in Taxol-induced apoptosis. The human breast carcinoma cell line MCF7 and its derivatives, MCF7/HER-2 and MDD2, were used in the study. We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF7 cells prior to apoptosis. PD98059 or SB203580, speci®c inhibitors of ERK and p38 kinase activities, signi®cantly decreased apoptosis, leaving the surviving cells arrested in G2/M. These inhibitors did not signi®cantly aect Taxol-induced alterations in the cell cycle regulatory proteins Rb, p53, p21/Waf1 and Cdk-2. In addition, inactivation of p53 did not aect cellular sensitivity to Taxol killing. However, cells with inactivated p53, unlike cells harboring wild type p53, failed to arrest in G2/M after treatment with Taxol and continued to divide or go into apoptosis. Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity. However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle. Oncogene (2001) 20, 147 ± 155.
Introduction
The anti-cancer agent paclitaxel (Taxol) is an eective drug in the treatment of metastatic breast and ovarian cancers, as well as in non-small-cell lung and head and neck cancers (Goldspiel, 1997; Holmes et al., 1991; McGuire et al. 1989) . The biological activity of Taxol is based on its ability to stabilize microtubules, inducing microtubule bundling (Schi et al., 1979; Turner and Margolis 1984; Torres and Horwitz, 1998) . Treatment of cells with Taxol disrupts the formation of normal spindles at metaphase, leading to an arrest of the cells in the G2/M phase of the cell cycle and eventually to apoptotic cell death (Woods et al., 1995) . Although it is likely that Taxol mediates its eects by interaction with the cytoskeleton, the molecular mechanisms by which microtubule deregulation leads to cytotoxicity are not well understood. The eects of Taxol may vary depending on cell type and drug concentration. For example, in A549 lung carcinoma cells, high concentrations of Taxol (49 nM) caused cell cycle arrest in G2/M, whereas lower Taxol concentrations lead to cell death after an aberrant mitosis (Torres and Horwitz, 1998) . On the other hand, treatment of U937 histiocytic lymphoma cells with 20 nM Taxol caused an accelerated processing through the cell cycle rather than cell cycle arrest, which facilitates apoptosis (Lieu et al., 1998) . These observations, as well as the dierences in the apoptotic machinery and response to Taxol between dierent cell types, raised the question as to what might be the intracellular signaling machinery that controls whether Taxol causes G2/M arrest or apoptosis.
Intracellular transmission of extracellular signals is mediated by several groups of sequentially-activated protein kinases, some of which (ERK, JNK, p38MAPK and BMK) belong to the superfamily of mitogen-activated protein kinases (MAPK) (Reszka et al., 1995; Seger and Krebs, 1995) . Other known intracellular signaling cascades include the PI3K-dependent activation of PDK/AKT and S6K pathways, IKK activation of NFkB (Shepherd et al., 1998; Yu et al., 1996) PKA activation of phosphorylase kinase and others (Campbell et al., 1995) . Interestingly, many of these intracellular cascades have been reported to take part in Taxol-induced apoptosis, as several studies have clearly demonstrated the involvement of the ERK cascade in Taxol-induced apoptosis (Blagosklonny et al., 1995 (Blagosklonny et al., , 2000 Huang et al., 1999; Lieu et al., 1998; Rasouli-Nia et al., 1998; Torres and Horwitz, 1998; Wolfson et al., 1997; Shtil et al., 1999) . Some reports have also claimed participation of the JNK cascade (Wang et al., 1998) p38 MAPK or even a PKA-induced pathway induction of apoptosis by Taxol (Shtil et al., 1999) . p53, cyclin-dependent kinase inhibitor p21/Waf1 and Bcl-2 have also been implicated in Taxol-induced apoptosis (Blagosklonny et al., 1995 (Blagosklonny et al., , 1996 Srivastava et al., 1998; Wahl et al., 1996; Huang et al., 1999; Wang et al., 1999) . The activity of these proteins seems to be regulated by the MAP kinase pathway requiring Raf-1 expression, although the exact connections between these components have not yet been fully elucidated (Blagnosklonny et al., 1996) .
In this study, we examined the mechanisms and pathways involved in Taxol induced apoptosis, namely two MAP kinase cascades involving (ERK and p38 MAPK) and the p53 pathways. Our results indicate that both MAPK cascades (ERK and p38 MAPK) are indispensable for Taxol's apoptotic activity in MCF7 cells since the addition of speci®c inhibitors of MEK and p38 MAPK (PD98059 and SB203580) prevented Taxol-induced apoptosis. In addition, although the presence of a wild type p53 protein was essential for the Taxol-induced G2/M arrest, inactivation of p53 did not suppress Taxol-induced apoptosis. In conclusion, the activation of ERK and p38 MAPK cascades are involved in the Taxol-induced apoptosis independent of p53 induced G2/M arrest.
Results
Taxol-induced apoptosis is mediated by the ERK and p38 MAPK cascades in MCF7 cell and Taxol upregulates certain cell cycle proteins Treatment of MCF7 cells with 50 ng/ml of Taxol for 1 ± 2 days induces massive apoptosis in MCF7 cells. To study the mechanisms leading to Taxol-induced apoptosis, we examined whether Taxol activated various MAP kinase pathways (ERK, p38 MAPK and JNK) as well as cell cycle associated pathways. By using antibodies directed against the activated form of ERK, p38 MAPK and JNK, we determined kinase activity in cytosolic extracts of Taxol-treated MCF7 cells as described before (Jaaro et al., 1997; Yung et al., 1997) . Under these conditions, ERK activity was elevated 3 ± 4-fold within 30 min, and decreased thereafter. p38 MAPK was similarly activated within 30 min after addition of Taxol (®vefold) and its activity decreased thereafter, reaching near basal levels 9 h after stimulation. JNK activity was less aected by Taxol in our experiments (1.8-fold above basal level) (Figure 1 ).
Several cell cycle and apoptosis-related proteins have recently been implicated in Taxol-induced apoptosis including p53, Bcl-2, p21/Waf1 and others (Blagosklonny et al., 1995 (Blagosklonny et al., , 1996 Rasouli-Nia et al., 1998; Wahl et al., 1996) . Therefore, by using immunoblotting, we analysed the state of these cell proteins in MCF-7 cells 2 days after treatment with 50 ng/ml of Taxol or with the MEK inhibitor PD98059 and Taxol (Figure 2) . Treatment of MCF7 cells with Taxol upregulated the expression of p53 and the p53-responsive gene p21/ Waf1. Taxol also modulated the phosphorylation of several cell cycle and apoptosis related molecules; upregulated BCL-2 phosphorylation and reduced the amount of phosphorylated retinoblastoma protein (Rb) and CDK 2 which are involved in cellular growth and proliferation.
Signi®cant elevation of ERK and p38MAPK activities in Taxol-treated MCF7 cells suggested that these kinases could mediate Taxol-induced apoptosis. We addressed this possibility by studying the eect of the speci®c inhibitors of MEK and p38MAPK (PD98059 and SB203580 respectively) (Lee et al., 1994; Srivastava et al., 1998; Wymann et al., 1996) on Taxol-induced apoptosis in MCF7 cells. Two days after treatment of MCF7 with 50 ng/ml of Taxol alone or in combination with 50 mM of PD98059 or 50 mM of SB203580, the cells were harvested and subjected to propidium iodide FACS analysis to determine the proportion of cells undergoing apoptosis. Our results (Figure 3) show that Taxol treatment induced 470% apoptosis while a (Figure 4 ). These results indicate the involvement of MEK/ERK as well as p38 MAPK cascades in the Taxol-induced apoptosis and suggest that it acts downstream of or that its action is not related to Taxol-induced cell cycle arrest.
To further investigate the role of ERK cascade in Taxol induced cell killing, we tested Taxol's eect on ras-transformed rat ®broblasts Rat-1 (line VC), and a derivative cell line, EKA, in which inhibition of ERK was achieved through the stable overexpression of a dominant negative MEK. The expression of a dominant negative MEK showed that the inhibition of MEK abolished Taxol induced apoptosis in the Rat-1 ®broblasts ( Figure 5 ).
Pretreatment of MCF7 cells with the inhibitor of MEK, PD98059, had only a slight eect on the expression of p53, p21/Waf1 or the phosphorylation of Rb and CDK2. The MAP kinase inhibitor, PD98059, did not signi®cantly aect the cell cycle regulatory proteins. However, inhibition of MAPK by PD98059 or SB203580 was ecient in the suppression of Taxol-induced apoptosis. These observations indicate that Taxol induced ERK-and p38MAPK-mediated apoptosis is independent of the cell cycle regulating proteins.
Taxol-induced apoptosis in MCF7 cells overexpressing HER-2/neu or inactive p53
In order to further study the roles of ERK, p38MAPK or p53 in Taxol induced apoptosis, we tested the eect of Taxol on MCF7 cells which overexpress Her-2/neu protein, namely MCF7/HER-2 (Peles et al., 1993) . Since overexpression of HER-2/neu results in the activation of ERK (Rasouli-Nia et al., 1998; Srivastava et al., 1998; Suzuki et al., 1998) , we compared the eects of Taxol on MCF7/HER-2 cells (overexpressing erbB-2/HER-2 as a result of transfection with the plasmid carrying erbB-2 cDNA) with control MCF7 (untransfected) (Peles et al., 1993) . FACS analysis showed that HER-2/neu overexpression did not signi®cantly aect cell cycle distribution under normal growth conditions ( Figure 6 ). Two days after Taxol treatment, the amount of cells undergoing apoptosis was greatly increased ( Figure 6 ). Addition of PD98059 to Taxol treated MCF7/HER-2 cells was not as eective in abolishing Taxol induced apoptosis as in regular MCF7 cells (compare Figures 6 to 3a ).
Since treatment with neu dierentiation factor (NDF/Heregulin) activates HER-2/neu in a similar fashion to HER-2 overexpression and upregulates MAPK (ERK-1 and ERK-2) (Karunagaran et al., 1996) , we treated MCF7 cells with NDF and looked at the Taxol induced apoptosis. Our results demonstrate that in the presence of NDF, PD98059 failed to eciently block Taxol induced apoptosis (compare Figures 7 to 3a) .
To test the role of p53 in Taxol-induced cell killing, we used MCF7 derived cells from which p53 function was blocked by a dominant negative p53 miniprotein, the MDD2 cell line (Shaulian et al., 1992) . Whereas mock transfected MCF7/MNI cells responded to treatment with Taxol and PD98059 in a similar manner as the parental line MCF7, the response of the MDD2 to Taxol 
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Figure 3 DNA ploidy analysis by¯ow cytometry on MCF7 cells. (a) Treated with no drug ± upper left; PD98059 (50 mM) ± upper right, Taxol 50 ng/ml ± lower left; or PD98059 (50 mM) and Taxol (50 ng/ml) ± lower right. Treatment with PD98059 was initiated 32 h prior to Taxol treatment. Cells were treated with Taxol for an additional 2 days then washed and resuspended in PBS containing 5 mg/ml of propidium iodide. FACS analysis was performed on a EPICS 753¯ow cytometry. (b) Cells were treated with SB203580 (50 mM) ± lower left; or with Taxol (50 ng/ml) and SB203580 (50 mM) ± lower right. SB was added 15 min before Taxol and cells were grown for an additional 2 days. The black arrows refer to the hypodiploid (apoptotic) peak
To further exclude the role of p53 in Taxol induced apoptosis and further establish its role in Taxol induced G2/M cell cycle arrest, we used pi®thrin a, a small molecular weight molecule which blocks a p53 dependent transcriptional activation (Komarov et al., 1999) . Treatment of MCF7 cells with Taxol and pi®thrin a, which rendered p53 inactive, did not abolish Taxol killing (Figure 8b) . However, pi®thrin a treatment together with Taxol and PD98059 resulted in an increase in the percentage of cells in G 0 G 1 compared to G2/M phase (Figure 8c ) which was in agreement with the G 0 G 1 block seen in cells with dominant negative p53 (MDD2) and other cells where p53 was rendered inactive by mutation (SKBR3, data NDF was added 24 h after plating the cells. All the other treatments were done as described in Figure 3 . Notice that in NDF treated cells, PD98059 was not as ecient in blocking Taxol killing as in untreated cells (see Figure 3) not shown). Our results point to the role of p53 in G2/ M growth arrest, but not in Taxol induced apoptosis. In summary, our results indicate that the MAP kinase (ERK and p38) pathways play a role in Taxol induced apoptosis whereas p53 is involved in Taxol-induced G2/M arrest.
Discussion
The anticancer agent paclitaxel (Taxol) has been shown to be an eective antitumor agent in a variety of human cancers including breast and ovarian cancers. Taxol stabilizes tubular polymerization during mitosis, leading to G2/M cell cycle arrest and apoptosis. We conducted this study in order to clarify the mechanism underlying the eects of Taxol. Our results indicate that Taxol-induced growth arrest and apoptosis are regulated in MCF7 cells by dierent mechanisms and demonstrate the importance of the MEK/ERK and p38MAPK activity in the induction of apoptosis, but not in G2/M cell cycle arrest. In addition, our results demonstrate the role of p53 in G2/M arrest after Taxol treatment and exclude its role in Taxol induced apoptosis. These conclusions are based on the following observations:
. Our results and previously published observations (Wahl et al., 1996) point out that the p53/p21 Waf1 pathway is not essential for the induction of apoptosis by Taxol. On the contrary, in cells that either express dominant negative p53 (MDD2), mutated p53 (SKBR3), or in cells treated with the p53 inhibitor, pi®thrin a, Taxol was extremely eective in the induction of apoptosis. However, p53 and p21 are probably responsible for the G2/M cell cycle arrest occurring after Taxol treatment since the cells which do not express active p53 failed to arrest in G2/M. In fact, it has been shown that p53 and p21/Waf1 are essential for sustained G2 arrest, preventing cells from entering mitosis (Bunz et al., 1998) . Entry into mitosis may be especially important for Taxol killing since the apoptotic activity of Taxol aects cells mainly during mitosis. Thus, while the MAPK pathways (MEK and p38) play essential roles in cellular killing by Taxol, p53 and p21 may act as survival factors, inducing G2 arrest by rescuing cells from proceeding through mitosis and subsequent cellular death. If p53 is inactivated, inhibition of MEK does not lead to a signi®cant G2 arrest thus allowing the cells to proceed through the cell cycle, most likely by enabling the cells to proceed through mitosis and eventually to apoptosis.
The association between p21/Waf1-mediated cell cycle arrest and resistance to apoptosis caused by radiation or chemotherapy has been reported previously in PC12 and H1299 cell lines where p21 induced cellular senescence and protected against the cytotoxic eects of radiation, doxorubicin and Taxol (Erhardt and Pittman, 1998; Suzuki et al., 1998; Waldman et al., 1996; Weinstein et al., 1998; We demonstrated in our previous studies that NDF/ heregulin also upregulates p53 and p21 (Bacus et al., 1996) , which, from our ®ndings, may protect cells from Taxol induced apoptosis. However, in this study, NDF/ heregulin did not alter Taxol cellular killing and actually reduced the ability of PD98059 to protect cells from Taxol killing. It seems likely that as previously reported NDF/heregulin also induced activation of ERK1, ERK2, JNK and p38 (Daly et al., 1997 (Daly et al., , 1999 Karunagaran et al., 1996; Wen et al., 1994) which may provide an explanation to this contradiction, as ERK1, ERK2, and p38 play a crucial role in Taxol killing. In addition, published data (Daly et al., 1999) demonstrated that induction of apoptosis and transition to G2M of the cell cycle by NDF/Heregulin is dependent on activation of p38 in breast cancer cell lines that overexpress HER-2/ neu. Most likely, treatment of cells with NDF together with Taxol has an additive eect on the activation of p38 and mitotic arrest, enhancing cellular killing by Taxol (Xia et al., 1995; Daly et al., 1999) .
It is important to keep in mind that activation of p38 occurs speci®cally by Taxol, which is a microtubule stabilizing agent and not by other microtubule depolymerizing agents such as colchicine, vincristine, nocodazole and podophyllotoxin (Shtil et al., 1999) .
The role of MEK in the induction of apoptosis was shown in another study, in which MEK potentiated radiation and chemotherapy induced apoptosis in A431, MDA-MB-468, Si ®brocarcinoma cells, HER293 cells, small cell lung carcinoma or HeLa cells (Carter et al., 1998; Kottke et al., 1999; Mitchell et al., 1995; Wang et al., 1998 Wang et al., , 2000b Widmann et al., 1997) . Our results regarding the role of activation of MEK and ERK in Taxol-induced apoptosis are also in agreement with the study of Pegram et al. (1997) , which showed that HER-2/neu overexpression (which is associated with activation of ERK-1 and ERK-2) rendered some cells more sensitive to Taxol killing.
It was reported that inhibition of MAPK activation by the MEK inhibitor, PD98059 caused termination of mitosis and interfered with the production of mitotic microtubules (Guadagno and Ferrell, 1998) , suggesting that p42 MAPK activity is required for producing normal mitotic microtubules. p38 as well as p42 MAPK have been shown to be associated with microtubules, mitotic spindles and mitotic checkpoints (Takenaka et al., 1998) . Since Taxol activity is associated with cellular killing mainly during mitosis, inhibition of MAPK and p38 will have an impact on its cell killing activity.
Our results dier from the data previously presented by Huang et al. (1999) in which inhibition of MEK by PD98059 did not aect Taxol's ability to kill in MCF7 cells. This can be explained by the dierence in duration of treatment with PD98059. In our study it was for 32 h prior to Taxol treatment, whereas PD98059 treatment in their study was initiated only for 16 h prior to Taxol treatment, which may not be enough for the inhibition of MEK to cause cell cycle arrest. Indeed, in a recent paper (Blagosklonny et al., 2000) , it has been demonstrated that when PD98059 was added prior to Taxol treatment, Taxol killing was inhibited. However, when it was added together with Taxol, no change in Taxol's ability to kill occurred, pointing to the importance of the time of treatment with PD98059.
Since inhibition of MEK and p38 inhibits all progression through mitosis, it is puzzling that Huang et al. (1999) could not see an impact on cellular killing by the inhibition of MEK. We also dier from Huang et al. (1999) ®ndings that in our study, p38 was phosphorylated by Taxol whereas Huang et al. (1999) did not ®nd phosphorylation of p38. This could be due to the dierent experimental conditions. We tested the upregulation of phosphorylated p38 in a serum free media whereas Huang et al. (1999) did not. However, our results agree with another study (Shtil et al., 1999) in which phosphorylation of p38 in MCF7 cells was speci®c to Taxol but not to other microtubule binding agents. In addition, p38 phosphorylation occurred very quickly after Taxol treatment in our study (15 ± 30 min) and in the Shtil et al. (1999) study wherein it was reduced almost to basal levels after 9 h. Huang et al. (1999) tested p38 phosphorylation after 2 h when levels of phosphorylation had also dropped in our study.
Although Huang et al. (1999) as well as others have stressed the importance of BCL-2 phosphorylation for Taxol killing, Blagosklonny et al. (2000) and Scatena et al (1998) showed that phosphorylation of BCL-2 occurred only after cells were allowed to progress through mitosis and that phosphorylation of BCL-2 and Raf was a result of mitotic arrest. Raf phosphorylation occurred after tubulin dysfunction and before apoptosis by Taxol, thus leaving the role of BCL-2 and Raf phosphorylation in Taxol induced apoptosis unde®ned. In summary, our data as well as other published data have demonstrated that any cellular growth arrest and progression to mitosis, either by inhibition of MEK or upregulation of p53/p21 pathways, provided protection from Taxol killing (Blagosklonny et al., 2000; Schmidt et al., 2000; Wang et al., 2000a; Chang et al., 1999; Horiuchi et al., 1997) .
Finally, our data provide a lead towards rational determination of the most ecient chemotherapy approaches to anti-cancer therapy especially as agents aimed at blocking MAP kinase pathways speci®cally MEK, have been suggested as treatment approaches (Sebolt-Leopold et al., 1999) . Based on our observations, we can preduct that in p53-inactive cancers that have increased MAPK activity, such as in cancers with mutated p53 and HER-2/neu overexpression, Taxol may be a good chemotherapeutic agent (KandiolerEckersberger et al., 2000) .
Materials and methods

Chemicals and reagents
Taxol (paclitaxel) (Sigma, St. Louis, MO, USA); PD98059 and SB203580 (Calbiochem, San Diego, CA, USA); and pi®thrin a (gift from AV Gudkov, Chicago, IL, USA) were dissolved in dimethyl sulfoxide and stored at 7708C. The concentrations used for the experiments were 50 ng/ml of Taxol, 50 mM of PD98059, 50 mM of SB203580, 10 ng/ml Neu dierentiation factor (NDF/Heregulin) and 15 mM of pi®thrin a. Treatment with Taxol, Neu dierentiation factor (NDF/ Heregulin) (a gift of Y Yarden, Rehovot, Israel), PD98059 and SB203580 was initiated 7 ± 48 h after cell plating and was continued for 1 ± 3 days. Treatment with pi®thrin a (PFT) was conducted 15 min prior to drug treatment. The ®nal concentration of dimethylsulfoxide (maximum 0.25%) in growth media did not aect cell growth, or any other parameters measured (i.e., induction of p53 or p21).
Cells
MCF7 cells were obtained from the Michigan Cancer Foundation (Detroit, MI, USA). A variant of MCF7 cells, MCFR7/HER-2, with 5 ± 8-fold elevated expression of HER-2/neu were obtained earlier by transduction with ErbB-2 cDNA (Bacus et al., 1996; Peles et al., 1993; Daly et al., 1997) . MN1 and MDD2 derivatives of MCF7 cells were described earlier (Shaulian et al., 1992) . MDD2 cells were obtained from MCF7 cells by transfection with a plasmid pCMVDD expressing p53 miniprotein with a strong dominant negative activity. MN1 cells were similarly generated by transfection of the control insert-free plasmid followed by G418 selection. MN1, MDD2 (Shaulian et al., 1992) , and MCF7 (ATCC, Rockville, MD, USA) express all four members of the erbB family (HER family), as demonstrated by immunohistochemical staining using speci®c antibodies to the various receptors (Yu et al., 1996; Bacus et al., 1996) . MCF7 derivatives (except MDD2) were similar to the original MCF7 cells in expressing wild type p53. Rat-1 cells transformed with the activated oncogene c-Ha-Ras (line VC) and their variants were expressing dominant negative MEK and displaying reverted transformed phenotype were obtained from the Weizmann Institute of Science (Rehovot, Israel).
The preparations of the Ras transformed cells containing dominant negative-MEK was done as follows: Stable transfection of EJ cells was made using the calcium phosphate method. Plasmid DNA (KA-MEK in pCDNA3 or pCDNA3 alone; 1 ± 2 mg) in 0.5 ml of 250 mM CaCl 2 was added dropwise to 0.5 ml of 26HBS (280 mM NaCl), 50 mM HEPES, 1.5 mM Na 2 HOP 4 , pH 7.0). The mix was incubated for 10 min at 238C and then was added to the medium. The plates were incubated for 16 h in 3% CO 2 . Then the cells were washed twice with DMEM and diluted to grow in DMEM+10% FCS (Gibco). Forty-eight hours later, G418 (0.8 mg/ml) was added for selection. Multiple G418 resistant clones were isolated and tested for MEK expression by Western blot. Two of the KA-MEK expressing clones in which the expression was about sixfold higher than the endogenous MEK were selected for further characterization and termed EKA. As a control, two vector-containing colonies were selected and termed EVC. The cells were maintained in RPMI 1640 medium (Gibco, Gaithersburg, MD, USA) supplemented with 10 ± 15% fetal bovine serum, penicillin (20 m/ml) streptomycin (20 mg/ml) in a humidi®ed incubator with 8% CO 2 at 378C. For the various experiments, exponentially growing cells were plated into Lab Tek eight-well chamber slides (Nunc, Naperville, IL, USA) or into 150 mm tissue culture plates. Cell numbers were determined by hemocytometer chamber counting and viability was monitored by exclusion of Trypan blue dye assay.
Cell cycle analysis
DNA content was determined by¯ow cytometry, using EPICS-753¯ow cytometer, as previously described (Dolbeare et al., 1983) . All described experiments involving FACS analysis of the cell cycle were repeated at least three times and representative results are presented.
Western blot analysis
Cell lysates were prepared and subjected to Western blot analysis as previously described (Keyomarsi et al., 1994; Yung et al., 1997) . Brie¯y, 50 mg of protein from each cell line was electrophoresed through the 13% sodium dodecyl sulfate polyacrylamide gel and transferred to Immobilon P (Millipore, Bedford, MA, USA). Blots were incubated with blocking buer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5% dry milk, 0.2% Tween-80) overnight at 48C then further incubated with various primary antibodies diluted in blocking buer for 3 h. As primary antibodies, we used rabbit antihuman p21 or anti-phosphorylated Rb and c-Jun (Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse monoclonal anti activated ERK and mouse monoclonal anti activated p38 (Weizmann Institute, Rehovot, Israel); mouse monoclonal anti activated JNK (Santa Cruz Biotechnology); and antibodies to p53 (Oncogene Science, Cambridge, MA, USA). The blots were washed and incubated with the appropriate secondary antibodies conjugated with horseradish peroxidase at a dilution of 1 : 5000 in blocking buer for 1 h and ®nally washed and developed with detection reagents (ECL) (Amersham Biochemicals, Chicago, IL, USA). ECL exposures for all Western blots were done at similar exposure time; all quantitations of the Western blots were performed by reprobing the blots with an antibody to actin followed by densitometry. The primary actin antibody used was a mouse monoclonal antibody to actin, clone C4 (Boehringer Manheim, Indianapolis, IN, USA). After scanning, autoradiographs were analysed using NIH Image software.
